Akcea Therapeutics, Inc. (AKCA)
AKCA Price and Sentiment
AKCA Latest news
Ionis Pharmaceuticals Inc (NASDAQ: IONS) said it expanded its distribution agreement with Swedish Orphan Biovitrum AB (“Sobi”) for Tegsedi in North America. Tegsedi is indicated for polyneuropathy (a condition where multiple peripheral nerves become damaged) in adults with hereditary transthyretin amyloidosis.
Ionis With Akcea: Still A Bargain
IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Investigations; Investors are Encouraged to Contact the Firm - AKCA, BLDR, DCOM, STND2020-09-26 04:05
NEW YORK, Sept. 26, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: Akcea Therapeutics, Inc. (NASDAQ: AKCA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Ionis...
Lifshitz Law Firm, P.C. Announces Investigation of Akcea Therapeutics, Inc. (NASDAQ: AKCA), BMC Stock Holdings, Inc. (NASDAQ: BMCH), Builders FirstSource, Inc. (NASDAQ: BLDR), Cancer Genetics, Inc. (NASDAQ: CGIX), Cellular Biomedicine Group, Inc. (NASDAQ:2020-09-25 16:55
NEW YORK, Sept. 25, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of AKCA to Ionis for $18.15 per share in cash. If you are a AKCA investor, and would like...
WAYLIVRA?® (volanesorsen), the First and Only Therapy for FCS, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in England2020-09-18 03:00
LONDON--(BUSINESS WIRE)--Akcea Therapeutics UK Ltd., a subsidiary of Akcea Therapeutics Inc.
Kaskela Law LLC Announces Stockholder Investigation of Akcea Therapeutics, Inc. (AKCA) and Encourages Investors to Contact the Firm2020-09-05 08:30
PHILADELPHIA, Sept. 5, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Akcea Therapeutics, Inc.
AKCEA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akcea Therapeutics, Inc. - AKCA2020-09-04 19:49
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of Akcea Therapeutics, Inc. - AKCA2020-09-01 17:05
NEW YORK, Sept. 1, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Akcea Therapeutics, Inc.
Ionis (IONS) is set to acquire the remaining 24% stake in Akcea Therapeutics (AKCA) in an all-cash deal.
Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of -113.33% and -47.10%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?